# Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)

> **NCT06677970** · PHASE3 · RECRUITING · sponsor: **Yonsei University** · enrollment: 176 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** BP lowering drugs (nicardipine, labetalol, urapidil)
- **DRUG:** BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil)

## Key facts

- **NCT ID:** NCT06677970
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2029-12-03
- **Final completion:** 2029-12-03
- **Target enrollment:** 176 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06677970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06677970, "Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06677970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*